DRUG · Unmapped registry intervention
BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
NCT02283320
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
BIND Therapeuticslead sponsor
Mapped research locations
Saint PetersburgRussia4DallasTexas, United States2PittsburghPennsylvania, United States2Los AngelesCalifornia, United States1San FranciscoCalifornia, United States1PortlandOregon, United States1PhoenixArizona, United States1Las VegasNevada, United States1MoscowRussia1La JollaCalifornia, United States1DuarteCalifornia, United States1SavannahGeorgia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02283320 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.